• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSivida's new Iluvien approval attempt focuses on safety

April 2, 2013 By drugdelivery

pSivida

Alimera Sciences

Watertown, Mass.-based pSivida (NSDQ:PSDV) and its licensee Alimera Sciences submitted a new response to the FDA in hopes of highlighting the safety profile of the Iluvien chronic diabetic macular edema treatment, a drug-device combination that the federal watchdog agency rejected in November 2011.

As promised, the companies submitted new information for their New Drug Application, offering clinical data gleaned from the completed phase III FAME trial, according to a press release.

The new results focus on patients with DME who didn’t respond to conventional therapy, the same patient group that European regulators used to green-light the therapy in the U.K.

The new application l is particularly meaningful for pSivida, which has a $25 million milestone payment hinging on approval.

"We are pleased to see the resubmission of the NDA to the FDA," pSivida president & CEO Dr. Paul Ashton said in prepared remarks. "To date, we have received over $30m from Alimera from its license of Iluvien for DME, and if the FDA approves Iluvien, we would be entitled to an additional $25 million milestone payment as well as 20% of net profits, as defined, on any sales in the U.S. by Alimera."

The road to approval has been a rocky one in both the U.S. and abroad. pSivida suffered a blow in November, when the U.K.’s National Institute for Health and Clinical Excellence struck down Iluvien because of its expense. Alimera reported that a patient access compromise is now under review by the U.K.’s regulatory agency and that it expects to begin shipments to the U.K. during the 2nd quarter for privately insured patients.

New of the new NDA submission didn’t spur much consideration from Wall Street, where PSDV shares were down 2.5% to $2.32 as of about 2:45 p.m. today.

Filed Under: Drug-Device Combinations, Preclinical Trials Tagged With: Alimera Sciences, pSivida Corp.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS